About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
The Hematology Journal
›
top-articles
The Hematology Journal
2.0
(top 20%)
impact factor
434
(top 50%)
papers
9.3K
(top 20%)
citations
47
(top 20%)
h
-index
2.3
(top 20%)
impact factor
557
all documents
9.6K
doc citations
73
(top 20%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
The Hematology Journal
2003
374
2
The effect of iron deficiency anemia on the function of the immune system
The Hematology Journal
2005
204
3
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML
The Hematology Journal
2003
198
4
Mesenchymal stem cell: use and perspectives
The Hematology Journal
2003
160
5
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma
The Hematology Journal
2004
129
6
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma
The Hematology Journal
2004
128
7
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma
The Hematology Journal
2004
126
8
Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants
The Hematology Journal
2001
118
9
The 5TMM series: a useful in vivo mouse model of human multiple myeloma
The Hematology Journal
2000
114
10
A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma
The Hematology Journal
2002
108
11
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib
The Hematology Journal
2004
107
12
Overwhelming postsplenectomy infection: is quality of patient knowledge enough for prevention?
The Hematology Journal
2004
106
13
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
The Hematology Journal
2000
104
14
XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis
The Hematology Journal
2004
95
15
Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma
The Hematology Journal
2001
92
16
Tumor necrosis factor α release is a major biological event associated with rituximab treatment
The Hematology Journal
2001
88
17
Role of coagulation testing in predicting bleeding risk
The Hematology Journal
2003
86
18
A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classification of lymphomas
The Hematology Journal
2004
86
19
Patterns of mortality in sickle cell disease in adults in France and England
The Hematology Journal
2002
86
20
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
The Hematology Journal
2003
86
21
Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma
The Hematology Journal
2000
83
22
A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients
The Hematology Journal
2001
80
23
Thalidomide in patients with advanced multiple myeloma: a study of 83 patients–report of the intergroupe francophone du myélome (IFM)
The Hematology Journal
2002
71
24
Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies
The Hematology Journal
2001
69
25
Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16)
The Hematology Journal
2002
69
26
Nuclear transplantation, embryonic stem cells and the potential for cell therapy
The Hematology Journal
2004
68
27
Antiphospholipid antibodies in lymphoma: prevalence and clinical significance
The Hematology Journal
2004
64
28
Tcf/Lef transcription factors during T-cell development: unique and overlapping functions
The Hematology Journal
2000
63
29
Prognostic significance of FLT3 ITD and D835 mutations in AML patients
The Hematology Journal
2003
63
30
Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?
The Hematology Journal
2000
62
31
Amplification of a novel c-Kit activating mutation Asn822-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia
The Hematology Journal
2002
62
32
Disseminated intravascular coagulation
The Hematology Journal
2003
60
33
Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas
The Hematology Journal
2003
57
34
Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales
The Hematology Journal
2002
56
35
Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden
The Hematology Journal
2000
55
36
The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma
The Hematology Journal
2002
55
37
Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis
The Hematology Journal
2003
55
38
Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells
The Hematology Journal
2002
54
39
Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study
The Hematology Journal
2004
51
40
Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy
The Hematology Journal
2003
51
41
Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies
The Hematology Journal
2000
50
42
Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis
The Hematology Journal
2000
50
43
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients
The Hematology Journal
2001
50
44
Antiphospholipid antibodies and thrombosis: strength of association
The Hematology Journal
2003
50
45
Myelodysplastic syndromes
The Hematology Journal
2004
49
46
Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases
The Hematology Journal
2004
49
47
Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy
The Hematology Journal
2001
48
48
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia
The Hematology Journal
2004
47
49
CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia
The Hematology Journal
2004
47
50
Stem cell growth factor: in situ hybridization analysis on the gene expression, molecular characterization and in vitro proliferative activity of a recombinant preparation on primitive hematopoietic progenitor cells
The Hematology Journal
2001
46
site/software ©
exaly
; All materials licenced under
CC by-SA
.